<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841112</url>
  </required_header>
  <id_info>
    <org_study_id>1289.4</org_study_id>
    <nct_id>NCT01841112</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety, tolerability and pharmacokinetics of single and multiple oral doses of BI 409306
      tablets in healthy Chinese and Japanese male volunteers of a known genotype as specified in
      the study protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number (%) of subjects with drug related Adverse Events</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma from time 0 to time of last quantifiable data point )</measure>
    <time_frame>up to 13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo (Multiple dose part)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2, EM, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extensive Metaboliser (EM), single dose part, medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3, EM, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extensive Metaboliser (EM), single dose part, high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3, PM, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poor Metaboliser (PM), single dose part, high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3, PM, multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poor Metaboliser (PM), multiple dose part, high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Single dose part)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1, EM, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extensive Metaboliser (EM), single dose part, low dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose 1, EM, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose 3, EM, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose 3, PM, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose 3, PM, multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Placebo (Multiple dose part)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Placebo (Single dose part)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>tablet</description>
    <arm_group_label>Dose 2, EM, single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male Chinese and Japanese volunteers

          2. Age between 20 and 45 years

          3. BMI between 18.5 and 25 kg/m2 (Body Mass Index)

          4. Known genotype as specified in the study protocol

          5. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

        1. Any deviation from healthy condition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.4.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

